KR102103407B1 - (3ｓ,3ｓ') 4,4'-디설판디일비스(3-아미노부탄 1-설폰산)과 l-라이신과의 결정성 상 - Google Patents

(3ｓ,3ｓ') 4,4'-디설판디일비스(3-아미노부탄 1-설폰산)과 l-라이신과의 결정성 상 Download PDF

Info

Publication number
KR102103407B1
KR102103407B1 KR1020157013661A KR20157013661A KR102103407B1 KR 102103407 B1 KR102103407 B1 KR 102103407B1 KR 1020157013661 A KR1020157013661 A KR 1020157013661A KR 20157013661 A KR20157013661 A KR 20157013661A KR 102103407 B1 KR102103407 B1 KR 102103407B1
Authority
KR
South Korea
Prior art keywords
absd
lysine
crystalline form
hypertension
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157013661A
Other languages
English (en)
Korean (ko)
Other versions
KR20150072454A (ko
Inventor
파브리스 발라부완느
쟝-마리 슈나이더
제라르 꼬끄렐
니꼴라 꾸브라
Original Assignee
깡뚬 제노믹스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 깡뚬 제노믹스 filed Critical 깡뚬 제노믹스
Publication of KR20150072454A publication Critical patent/KR20150072454A/ko
Application granted granted Critical
Publication of KR102103407B1 publication Critical patent/KR102103407B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/26—Separation; Purification; Stabilisation; Use of additives
    • C07C319/28—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157013661A 2012-10-22 2013-10-22 (3ｓ,3ｓ') 4,4'-디설판디일비스(3-아미노부탄 1-설폰산)과 l-라이신과의 결정성 상 Expired - Fee Related KR102103407B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306307.5 2012-10-22
EP12306307.5A EP2722327A1 (en) 2012-10-22 2012-10-22 Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine
PCT/EP2013/072028 WO2014064077A1 (en) 2012-10-22 2013-10-22 Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine

Publications (2)

Publication Number Publication Date
KR20150072454A KR20150072454A (ko) 2015-06-29
KR102103407B1 true KR102103407B1 (ko) 2020-04-22

Family

ID=47278723

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157013661A Expired - Fee Related KR102103407B1 (ko) 2012-10-22 2013-10-22 (3ｓ,3ｓ') 4,4'-디설판디일비스(3-아미노부탄 1-설폰산)과 l-라이신과의 결정성 상

Country Status (30)

Country Link
US (2) US9278921B2 (https=)
EP (2) EP2722327A1 (https=)
JP (1) JP6317358B2 (https=)
KR (1) KR102103407B1 (https=)
CN (1) CN104768927B (https=)
AR (1) AR093070A1 (https=)
AU (1) AU2013336738B2 (https=)
BR (1) BR112015008931B1 (https=)
CA (1) CA2884914C (https=)
CY (1) CY1119913T1 (https=)
DK (1) DK2909169T3 (https=)
EA (1) EA024460B1 (https=)
ES (1) ES2658413T3 (https=)
HR (1) HRP20180189T1 (https=)
HU (1) HUE036037T2 (https=)
IL (1) IL237733B (https=)
IN (1) IN2015DN02807A (https=)
LT (1) LT2909169T (https=)
ME (1) ME02955B (https=)
MX (1) MX353693B (https=)
NO (1) NO2909169T3 (https=)
NZ (1) NZ706070A (https=)
PL (1) PL2909169T3 (https=)
PT (1) PT2909169T (https=)
RS (1) RS56896B1 (https=)
SI (1) SI2909169T1 (https=)
SM (1) SMT201800086T1 (https=)
TW (1) TWI643842B (https=)
WO (1) WO2014064077A1 (https=)
ZA (1) ZA201503574B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103951562B (zh) * 2014-05-09 2016-04-20 四川九章生物化工科技发展有限公司 一种绿原酸晶型及其制备方法
WO2022225712A1 (en) * 2021-04-22 2022-10-27 Teva Pharmaceuticals International Gmbh Solid state forms of firibastat and processes for preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135602A1 (en) 2002-07-16 2006-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same
WO2012045849A1 (en) 2010-10-07 2012-04-12 Quantum Genomics Method for the preparation of (3s,3s') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US9447050B2 (en) * 2011-04-05 2016-09-20 The Translational Genomics Research Institute Solid forms of curcumin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135602A1 (en) 2002-07-16 2006-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same
WO2012045849A1 (en) 2010-10-07 2012-04-12 Quantum Genomics Method for the preparation of (3s,3s') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid)

Also Published As

Publication number Publication date
CA2884914A1 (en) 2014-05-01
ES2658413T3 (es) 2018-03-09
CA2884914C (en) 2021-01-05
US20150284325A1 (en) 2015-10-08
MX2015005059A (es) 2015-11-23
CY1119913T1 (el) 2018-06-27
TW201418202A (zh) 2014-05-16
BR112015008931A2 (pt) 2017-07-04
WO2014064077A1 (en) 2014-05-01
HK1212321A1 (en) 2016-06-10
AU2013336738A1 (en) 2015-04-09
BR112015008931B1 (pt) 2021-05-18
RS56896B1 (sr) 2018-04-30
ZA201503574B (en) 2016-01-27
EA201500438A1 (ru) 2015-09-30
CN104768927B (zh) 2017-06-09
JP2015536316A (ja) 2015-12-21
AU2013336738B2 (en) 2017-05-18
KR20150072454A (ko) 2015-06-29
JP6317358B2 (ja) 2018-04-25
PL2909169T3 (pl) 2018-07-31
PT2909169T (pt) 2018-02-26
EP2909169A1 (en) 2015-08-26
NO2909169T3 (https=) 2018-06-02
MX353693B (es) 2018-01-24
IL237733B (en) 2019-03-31
DK2909169T3 (en) 2018-02-26
NZ706070A (en) 2018-11-30
US9487477B2 (en) 2016-11-08
SI2909169T1 (en) 2018-04-30
LT2909169T (lt) 2018-04-25
US9278921B2 (en) 2016-03-08
ME02955B (me) 2018-07-20
HUE036037T2 (hu) 2018-06-28
AR093070A1 (es) 2015-05-13
SMT201800086T1 (it) 2018-05-02
EA024460B1 (ru) 2016-09-30
IN2015DN02807A (https=) 2015-09-11
EP2722327A1 (en) 2014-04-23
US20160221940A1 (en) 2016-08-04
CN104768927A (zh) 2015-07-08
EP2909169B1 (en) 2018-01-03
TWI643842B (zh) 2018-12-11
HRP20180189T1 (hr) 2018-04-20

Similar Documents

Publication Publication Date Title
ES2652187T3 (es) Fenilacetato de l-ornitina y métodos para elaborar el mismo
JP2022176961A (ja) ｛［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
JP6087284B2 (ja) Ｌ−オルニチンフェニルアセテートを製造するための方法
JP2009209129A (ja) ４−カルバモイル−５−ヒドロキシ−イミダゾール誘導体のスルホン酸塩化合物
KR100878698B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
KR102103407B1 (ko) (3ｓ,3ｓ&#39;) 4,4&#39;-디설판디일비스(3-아미노부탄 1-설폰산)과 l-라이신과의 결정성 상
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
JP2017505788A (ja) イオンチャネルモジュレーターの固体形態
HK1212321B (en) Crystalline phase of (3s.3s&#39;) 4,4&#39;-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine
KR101307712B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및 이를 포함하는 약학 조성물
US11440908B2 (en) Crystalline forms of dasatinib
KR20130036210A (ko) 신규 다형체 및 염
KR101007927B1 (ko) 시부트라민-ｌ-카르니틴 다이술폰산염, 이의 제조방법 및 이를 포함하는 약제학적 조성물
HK1141290A (en) Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250417

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250417

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250417